Potential of Pentraxin-2 Therapeutics

Fibrosis is a common pathway that can affect nearly all tissues and organ systems, including lung, kidney, liver, bone marrow, and the eye. If highly progressive, the fibrotic process eventually leads to organ dysfunction and death. It is estimated that approximately 45% of deaths in the United States can be attributed to fibrotic disorders. Despite this large unmet medical need, there are no approved, disease-modifying therapies that can treat systemic fibrotic diseases.

Fibrosis: One Process; Many Diseases

A leading cause of death and disability, fibrosis is the common pathology of
a number of serious and chronic diseases with unmet patient needs:
Fibrosis-Driven Diseases


Promedior and its collaborators have demonstrated the ability of Pentraxin-2 to block the initiation and progression of fibrosis in several models of fibrotic disease, across many major tissue types, confirming its potential as a novel anti-fibrotic agent. Many of these findings have been published in peer-reviewed journals and presented at medical and scientific meetings.

Extensive Preclinical Data Validate the Broad Potential of PTX-2

Promedior and collaborators have demonstrated the efficacy of Pentraxin-2 in a diversity
of tissues in preclinical studies, confirming the broad potential of Promedior's Pentraxin-2
therapeutics for a number of diseases:
Fibrosis-Driven Diseases